The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Related News Articles

Headline
The Food and Drug Administration July 22 released an early alert for Novum IQ large volume infusion pumps by Baxter. The company stated that the pump has…
Headline
Senior leaders from the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, along with White House…
Headline
President Trump July 7 issued an executive order, “Extending the Modification of the Reciprocal Tariff Rates,” which extends the original July 9 reciprocal…
Headline
The AHA submitted a statement today to the House Energy and Commerce Subcommittee on Health for a hearing today on the health care supply chain. The AHA…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an…
Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…